Skip to main content

Table 3 Summary of efficacy results for better and poorer efficacy subgroups by treatment arms

From: A VELOUR post hoc subset analysis: prognostic groups and treatment outcomes in patients with metastatic colorectal cancer treated with aflibercept and FOLFIRI

  Better efficacy subgroup Poor efficacy subgroup
  FOLFIRI-placebo FOLFIRI-aflibercept FOLFIRI-placebo FOLFIRI-aflibercept
Overall survival rates    
6 months 83% 88% 71% 70%
12 months 54% 64% 43% 42%
18 months 34% 46% 24% 24%
24 months 22% 35% 12% 15%
30 months 12% 27% 10% 13%
Progression free survival rates    
6 months 38% 63%   
12 months 15% 20%   
18 months 5% 6%   
Objective response rates    
  11% 24%